



Vivimed

For Immediate Release

May 18, 2017

Vivimed announces JV partnership to grow its US Finished Dosage business, association with Strides Shasun aimed at building product pipelines, scale and competitiveness

Hyderabad, India, May 18, 2017 – Vivimed Labs Limited (“Vivimed” or the Company), a Pharmaceuticals and Specialty Chemicals’ company, announced today the signing of a definitive agreement with Strides Shasun to grow its presence in the US finished dosage formulation (FDF) business segment. This 50-50 JV in India, will house the Company’s US FDA inspected FDF facility in Alathur, Tamil Nadu, and the 50-50 JV in Singapore will house its current portfolio of ANDAs.

Vivimed believes the JV partnership with Strides Shasun offers its portfolio of products the synergies from Strides Shasun’s existing front end in the US market. This coupled with Vivimed’s product development pipeline for the US offers the JV a strong opportunity to grow its footprint aggressively. The Alathur facility was acquired by Vivimed in 2013 and, has successfully completed 2 US FDA inspections since then, in addition to expanding its capacity to 1.5bn SOD per annum.

Commenting on the development, **Mr. Santosh Varalwar, Managing Director** said:

“This transaction is aimed at bringing scale to our presence in the US FDF market; this equal JV brings together an optimum mix of our manufacturing strength, product development capability and, Strides Shasun’s front end presence and marketing expertise. We believe this will place all the stakeholders in a position of strength and lend greater scale to our aspirations for the US generic market. The US market is evolving at a rapid pace in terms of market access, product selection and consolidation of the distributor landscape. The coming together of Vivimed’s US generic franchise and Strides Shasun is likely to multiply our strengths and, script a win-win equation for both the partners in the coming years.

On a strategic basis, we believe this new development will give greater focus to our aspirations for building scale and differentiation in our US generic product pipeline. At Vivimed, we see ourselves as an entity with access to compelling opportunities in each of the segments we are now investing in; the regulated market API/CDMO franchise housed in our subsidiary UQUIFA, our niche specialty chemicals franchise and the growing FDF business we have for India and the RoW markets”.

#IMAP India is the exclusive advisor to Vivimed Labs Limited for the above transaction with Strides Shasun.

*** **

For VIVIMED LABS LTD.

Managing Director



Vivimed

Analyst and Investor Enquiries

Ramesh Challa, CFO
Vivimed Labs Limited

+91 40 2717 6005
ramesh.challa@vivimedlabs.com

B. Rajaprasad
Vivimed Labs Limited

+91 40 2717 6005
rajaprasad.b@vivimedlabs.com

For further information on Vivimed, visit www.vivimedlabs.com

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For VIVIMED LABS LTD.

A handwritten signature in blue ink, appearing to be 'w.h.', is written over a circular stamp. A diagonal blue line is drawn across the stamp and signature.
Managing Director